Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So if this NEWS is good what do u see as possible my friend
You are correct, they have to find a way to get a piece of the pie even if it hurts others.jp is leading the charge ( you know that family that's part of that private company called the FED ) have ur $ ready to buy when it turns up.
To ALL, Any thoughts on the next coin on coin base if not Ripple? Even though CB dispelled that on the 5th I still think it's a front runner even though it's centralized .
Try coinmama. , get ETH. Then send to brittrex , swap brittrex for XRP. IF u want to save time because this will go any day with a coinbase announcement . Cheaper to move ETH then BTC. IF you move anything from a ETH wallet make sure to set gas 40-50K if you want it moved fast, i.e. ( -10 minn ). No expert just practice . If one has a good way of moving Profit other then coinbase to cash out 20K +. Plssss let me know. GMENT wants a piece of everything etc....
Anyone help, Can u buy this thru fidelity & how. It's not coming up for me, tks.
To lo, more like 1-1.50$ maybe $2
What were u looking for, pls share
So we may hit 20k before pullback, wow
Does anyone see a pullback coming for bitcoin any time soon, poss before the end of the year & how much of a pull back?
9907.00 & climbing
This is off base but does anyone have any thoughts on Crypterium ICO ( likes / dislikes ) I'm new to cryptocurrency. Any feed back would be great or better options, by the way I'm all in on this stock.
Now that's how you do the dammmmm thing, go longs 2.3 mil & adding
When is the Q1 due
It would seem that they should have a picture by now, they can take one off the site u would think, I'm just saying.
Can someone explain this https://www.saratogawine.com/Bellissima
Is this our wine
U & anyone else keep saying this sounds like a JOKE. People know what u own, go longs.
Canada legalize marijuana, any idea of possible plays, do share.
If #1 holds true , possible buyout down the road
So is that the MM SENDING A SIGNAL, if I were to place a buy for 911 would itNOT get filled.
When it runs, it's going past .06, more like .10-.15 maybe higher then retract as normal but good revenue will keep it going.
It's going down drinks on the table, yesss
I know what I own, but missed opportunity to show the brand on live tv.
What is the stock u are referring to give me the missing # pls
Fidelity stop orders last week because for the past 6 mos, it was current, no go back and forth, it may come off in a couple of days, they do see current as of this morning.
Fidelity NOT TAKING TRADES ON ICNB
You were tipsy after 3 glasses so it didn't matter,lol. Up we go.
Just out of curiosity, which companies you gave up on or lost patience?
What news icon are you referring to.
What are u people seeing
So r u saying the PPS is going up for a change NEW4THIS
You are receiving this email because you signed up to receive email updates from InvestorTrendz.com. If you do not want to receive these emails anymore, please unsubscribe.
April 8th, 2015
Symbol: RGBP
Price: $.26 cents up 13%
Today's focus is ONLY going to be RGBP for several main reasons which you will see very shortly.
Yesterdays stock was up over 133%, providing plenty of opportunity for investors to make DOUBLE on their money. Like turning $5,000 into $10,000+ in a day.
RIght now, I'm puttin focus and attention on RGBP. Watch what happens in the next couple days.
Read below:
SAN DIEGO, CA--(Marketwired - Apr 7, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference ishttp://mds.kenes.com
Myelodysplastic Syndrome is a disease of bone marrow failure, where blood cells fail to form because bone marrow stem cells fail to differentiate. The Company has filed one IND in this space on HemaXellerate treatment for aplastic anemia and is working on preclinical development of DiffronC, an siRNA based therapeutic targeting cancer stem cell genes involved in blood cell differentiation.
The three presentations are:
HEMAXELLERATE I™, AUTOLOGOUS ADIPOSE STROMAL VASCULAR FRACTION CELLS, FOR SEVERE APLASTIC ANEMIA
NR2F6 (EAR-2) IS A NOVEL LEUKEMIA AND MDS ONCOGENE, OVER-EXPRESSED IN PATIENTS, THAT INHIBITS HEMATOPOIETIC DIFFERENTIATION AND BLOCKS ERYTHROPOIETIC DIFFERENTIATION AT THE PROERYTHROCYTE STAGE
TECHNIQUE FOR ESTABLISHMENT OF LONG TERM IN VITRO CULTURES OF PRIMARY MDS CELLS
Regen's Chairman & CEO David Koos stated, "These three presentations represent an exciting turning point for the Company. We are gaining credibility and exposure in our fields of research among the top biotechnology scientists around the world. This should lead to potential collaborations that aid in our future progress."
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
www.regenbiopharma.com
Check out the website for more infomation about RGBP.
Happy Trading,
InvestorTrendz
PS. Please, I encourage you to do your research quickly on this one!
PPS- My last 3 picks jumped up and created massive wealth for many investors!
17 (B) Disclaimer
www.investortrendz.com is owned and operated by Madman Services LLC which is an American corporation.
investortrendz.com electronically disseminates information on its website, in newsletters, featured reports, spam compliant double-opt in email communications or otherwise pertaining to Profiled Companies’ the securities of which are most frequently penny stocks and common stock quoted on the OTCQB or pin.k shee.ts.
Because investortrendz.com receives compensation for investortrendz.com’s dissemination of the Information (as disclosed in our Compensation Disclosure Section), including at times in the form of common stock shares (the “Shares”), investortrendz.com should not be considered to be independent or objective and the Information may enable investortrendz.com to publicly sell its shares when it would have otherwise been unable to do so.
investortrendz.com does not perform research, due diligence or undertake an analysis of the Profiled Companies investortrendz.com. does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Your use of the Information is at your own risk. investortrendz.com disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, you hereby agree to indemnify and hold investortrendz.com harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information.
The Information is presented only as a brief “snapshot” of the Profiled Company and should only be used, at most, and if at all, as a method of obtaining the names of penny stocks and a starting point for you to conduct a thorough investigation of the Profiled Company and its securities and to consult your financial, legal or other advisor(s) and avail yourself to the filings and information that may be accessed at www.sec.gov . or www.pic.k_s_h_e_ets.com or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the pin.k shee.ts; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (e) consulting investment guides at www.sec.gov and www.finra.com pertaining to the risks of investing in penny stocks. Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, you should conduct due diligence and its own review of the Profiled Companies and its securities.
The Profiled Companies are subject to possible risks, including but not limited to: (a) the Information pertains to penny stocks that are subject to the SEC’s penny stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company’s securities; (b) the Profiled Company’s penny stock may be thinly traded, which may lead to difficulties of selling its securities; (c) a Profiled Company that is an SEC reporting issuer who is a Profiled Company may be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or the Pink Sheet quoted company may be delinquent in its Pin.k Sheet reporting obligations as indicated by pink shee.ts New Service’s posting a negative “sign” pertaining to the Profiled Company at www.pin.k_sh_eets.com , as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the pink shee.ts; (ii) “pink shee.ts – No Information”, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the pink shee.ts; and (iii) “Caveat Emptor”, signifying “Buyer Beware” that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions; (d) whether the Profiled Company is a development stage company with little or no operations, the securities of which should be considered extremely speculative for investment purposes; (e) investortrendz.com’s selling of an Profiled Company’s securities may cause its stock price to significantly decline, especially when such securities are thinly traded; (f) many companies that have their securities quoted on the OTCBB or pink shee.ts (as well as even Exchange listed companies) have been negatively affected by the current economic downturn and lack of adequate financing to meet their operational goals or expansion plans; (g) any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future stock price of an Profiled Company’s securities or its operational results; (h) many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes; (i) investortrendz.com may receive compensation in shares of the Profiled Company and it or its associates, affiliated entities, officers, directors or immediate family members may sell the Shares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, investortrendz.com’s selling activities may cause significant volatility in the Profiled Company’s stock price and/or significantly depress the Profiled Company’s stock price; (j) investortrendz.com may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including drops in the price of the Profiled Company’s stock price and/or significantly depress the Profiled Company’s stock price; (k) future success of many OTCQB and Pink Sheet quoted companies is dependent upon receiving adequate financing or raising sufficient capital, which they may be unable to obtain; (l) there is an inherent and actual conflict of interest that exists between our Readers’ interests and investortrendz.com’s interests because investortrendz.com’s owners, investortrendz.com: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buys and sells the Profiled Company’s shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time; (m) we do not receive any direct verification from the Profiled Company regarding the Information; (n) a third party shareholder may have a potential or actual conflict of interest in paying investortrendz.com for the dissemination of the publication while still holding the Profiled Company’s shares of common stock that he or she may sell after the third party shareholder has paid investortrendz.com with his or her shares; (o) the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Profiled Company’s future stock price or future financial performance since, among other reasons, such “comparison” companies are listed on Exchanges (i.e., the New York Stock Exchange) and trade at stock prices that are thousands of percent higher than the companies we profile; and (p) Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further investigation of the Profiled Company and its securities ; and (q) investortrendz.com may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Company, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers; no securities compensation is paid to the Service Providers; and (r) our employees post messages on their individual message boards as a method of disseminating the Information on behalf of the Profiled Companies which should never be used as a means of conducting analysis into the Profiled Company and should only be used as a starting point to obtain the names of pi_nk sh_e_et or OTCQB companies. Income Disclaimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results or receive any income from the purchase of a Profiled Company’s securities. By entering www.investortrendz.com you agree that investortrendz.com is not liable for any success or loss of any investment you make. There are no guarantees concerning the level of success you may experience if you buy or sell the securities of the Profiled Companies. Income statements on investortrendz.com may be made by fictitious persons and should not be considered as accurate or true representations or statements of actual income derived from the securities of the Profiled Companies. You should not rely upon the Information for any purpose. www.investortrendz.com is owned and operated by Madman Services LLC. Madman Services LLC has NOT been compensated for this publication on RGBP. To view our entire disclaimer go to http://investortrendz.com/free-reports/
This message was sent to mr.lrox@yahoo.com from:
InvestorTrendz.com | send@investortrendz.com | tradefortheweek | 28th ave 126th street | New york, New York 10001
Email Marketing by iContact - Try It Free!
Unsubscribe
Got this in email today
You are receiving this email because you signed up to receive email updates from InvestorTrendz.com. If you do not want to receive these emails anymore, please unsubscribe.
March 6, 2015
Symbol: RGBP
Price: $.22-$.23
The Bio-Tech sector is one of the hottest sectors right now in regards to explosive growth.
This new pick of mine is sure to grab your interest.
You may be guessing that an up and coming bio-tech company with stem sell studies leading to cancer treatments would be trading in the $10-$20 range. If that is your guess, you are right!
But, this gem is at it's infancy. It's trading at a low of $.22. That's right 22 cents!
Could this be the next bio-tech giant?
Below is an article from Yahoo Finance:
SAN DIEGO, CA--(Marketwired - Apr 6, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is forTreatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Patent application #14588374 covers methods, compositions, and treatment protocols for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F2 gene expression or activity of protein. This patent application also covers induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states. While # 14588373 covers utilizing of gene silencing technologies pertaining to suppression of the nuclear receptor NR2F2 for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors and methods of using such compounds to treat cancer.
These new patent applications add to the Company's existing portfolio of intellectual property covering therapeutics that can be used as differentiation therapy, a new form of cancer treatment that works by instructing cancer stem cells to mature in to normal cells that have a limited lifespan. This intellectual property will compliment other intellectual property in the Gene Silencing of Cancer Stem Cells Therapeutics Platform including in-house and acquired IP from the University of Toronto for the cancer stem cell gene NR2F6 (also known as EAR-2) and the Company's CTCFL technology also known as BORIS).
We are working on establishing an area of expertise in Gene Silencing of Cancer Stem Cell target genes, that builds upon a licensing agreement with Benitec Biopharma for use in conjunction with their shRNA gene silencing platform. This allows us to take advantage of synergisms by establishing strengths and programs that we can use to comprehensively target the important genes in the cancer stem cell space. This will lead to economies of scale in therapy development.
The cancer stem cell is the most important and sought after cellular target of cancer therapy. Not every cancer cell within a tumor is able to divide. Cancer stem cells are the cells within the tumor that can divide an infinite number of times and are the cells within the tumor that allow a tumor to maintain its cancerous ability, therefore it is important to target those cells specifically.
"Patent protection is also essential for thoroughly protecting the Company's space in this field. While existing patents cover NR2F6, a closely related member of that protein family, NR2F2 has some redundant and overlapping functions. Protecting this space is important not only to cover our target, but because resistance of the cancer to therapy is one the biggest causes of cancer therapy failure," according to Dr. Thomas Ichim, the Company's Chief Scientific Officer.
"The circuitry of the cell is like a stream. Many times, cancer therapeutics fail because the circuitry of the cell is equipped with redundant pathways that are turned on when the initial pathway is blocked, like the increased flow to tributaries when one branch of a stream is dammed. By silencing the NR2F6 related family member NR2F2 the Company believes that we can create more efficacious therapeutics by prospectively addressing possible mechanisms of resistance before they arise," noted Christine Ichim, PhD, the Company's Director of Molecular Therapeutics.
NR2F2 (COUP-TFII) is well known for its role in cancer by the mechanism of controlling key pathways in embryogenesis and tumor formation including the Notch signalling pathway, TGF-beta and retinoic acid signalling.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK:RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
InvestorTrendz
PS. Please, I encourage you to do your research quickly on this one!
PPS- My last 3 picks jumped up and created massive wealth for many investors!
17 (B) Disclaimer
www.investortrendz.com is owned and operated by Madman Services LLC which is an American corporation.
investortrendz.com electronically disseminates information on its website, in newsletters, featured reports, spam compliant double-opt in email communications or otherwise pertaining to Profiled Companies’ the securities of which are most frequently penny stocks and common stock quoted on the OTCQB or pin.k shee.ts.
Because investortrendz.com receives compensation for investortrendz.com’s dissemination of the Information (as disclosed in our Compensation Disclosure Section), including at times in the form of common stock shares (the “Shares”), investortrendz.com should not be considered to be independent or objective and the Information may enable investortrendz.com to publicly sell its shares when it would have otherwise been unable to do so.
investortrendz.com does not perform research, due diligence or undertake an analysis of the Profiled Companies investortrendz.com. does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Your use of the Information is at your own risk. investortrendz.com disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, you hereby agree to indemnify and hold investortrendz.com harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information.
The Information is presented only as a brief “snapshot” of the Profiled Company and should only be used, at most, and if at all, as a method of obtaining the names of penny stocks and a starting point for you to conduct a thorough investigation of the Profiled Company and its securities and to consult your financial, legal or other advisor(s) and avail yourself to the filings and information that may be accessed at www.sec.gov . or www.pic.k_s_h_e_ets.com or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the pin.k shee.ts; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (e) consulting investment guides at www.sec.gov and www.finra.com pertaining to the risks of investing in penny stocks. Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, you should conduct due diligence and its own review of the Profiled Companies and its securities.
The Profiled Companies are subject to possible risks, including but not limited to: (a) the Information pertains to penny stocks that are subject to the SEC’s penny stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company’s securities; (b) the Profiled Company’s penny stock may be thinly traded, which may lead to difficulties of selling its securities; (c) a Profiled Company that is an SEC reporting issuer who is a Profiled Company may be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or the Pink Sheet quoted company may be delinquent in its Pin.k Sheet reporting obligations as indicated by pink shee.ts New Service’s posting a negative “sign” pertaining to the Profiled Company at www.pin.k_sh_eets.com , as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the pink shee.ts; (ii) “pink shee.ts – No Information”, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the pink shee.ts; and (iii) “Caveat Emptor”, signifying “Buyer Beware” that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions; (d) whether the Profiled Company is a development stage company with little or no operations, the securities of which should be considered extremely speculative for investment purposes; (e) investortrendz.com’s selling of an Profiled Company’s securities may cause its stock price to significantly decline, especially when such securities are thinly traded; (f) many companies that have their securities quoted on the OTCBB or pink shee.ts (as well as even Exchange listed companies) have been negatively affected by the current economic downturn and lack of adequate financing to meet their operational goals or expansion plans; (g) any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future stock price of an Profiled Company’s securities or its operational results; (h) many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes; (i) investortrendz.com may receive compensation in shares of the Profiled Company and it or its associates, affiliated entities, officers, directors or immediate family members may sell the Shares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, investortrendz.com’s selling activities may cause significant volatility in the Profiled Company’s stock price and/or significantly depress the Profiled Company’s stock price; (j) investortrendz.com may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including drops in the price of the Profiled Company’s stock price and/or significantly depress the Profiled Company’s stock price; (k) future success of many OTCQB and Pink Sheet quoted companies is dependent upon receiving adequate financing or raising sufficient capital, which they may be unable to obtain; (l) there is an inherent and actual conflict of interest that exists between our Readers’ interests and investortrendz.com’s interests because investortrendz.com’s owners, investortrendz.com: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buys and sells the Profiled Company’s shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time; (m) we do not receive any direct verification from the Profiled Company regarding the Information; (n) a third party shareholder may have a potential or actual conflict of interest in paying investortrendz.com for the dissemination of the publication while still holding the Profiled Company’s shares of common stock that he or she may sell after the third party shareholder has paid investortrendz.com with his or her shares; (o) the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Profiled Company’s future stock price or future financial performance since, among other reasons, such “comparison” companies are listed on Exchanges (i.e., the New York Stock Exchange) and trade at stock prices that are thousands of percent higher than the companies we profile; and (p) Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further investigation of the Profiled Company and its securities ; and (q) investortrendz.com may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Company, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers; no securities compensation is paid to the Service Providers; and (r) our employees post messages on their individual message boards as a method of disseminating the Information on behalf of the Profiled Companies which should never be used as a means of conducting analysis into the Profiled Company and should only be used as a starting point to obtain the names of pi_nk sh_e_et or OTCQB companies. Income Disclaimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results or receive any income from the purchase of a Profiled Company’s securities. By entering www.investortrendz.com you agree that investortrendz.com is not liable for any success or loss of any investment you make. There are no guarantees concerning the level of success you may experience if you buy or sell the securities of the Profiled Companies. Income statements on investortrendz.com may be made by fictitious persons and should not be considered as accurate or true representations or statements of actual income derived from the securities of the Profiled Companies. You should not rely upon the Information for any purpose. www.investortrendz.com is owned and operated by Madman Services LLC. Madman Services LLC has NOT been compensated for this publication on RGBP. To view our entire disclaimer go to http://investortrendz.com/free-reports/
This message was sent to mr.lrox@yahoo.com from:
InvestorTrendz.com | send@investortrendz.com | tradefortheweek | 28th ave 126th street | New york, New York 10001
Email Marketing by iContact - Try It Free!
Unsubscribe
Got this in email today
{ALERT} Bio-Tech Company Symbol Release...
You are receiving this email because you signed up to receive email updates from InvestorTrendz.com. If you do not want to receive these emails anymore, please unsubscribe.
March 6, 2015
Symbol: RGBP
Price: $.22-$.23
The Bio-Tech sector is one of the hottest sectors right now in regards to explosive growth.
This new pick of mine is sure to grab your interest.
You may be guessing that an up and coming bio-tech company with stem sell studies leading to cancer treatments would be trading in the $10-$20 range. If that is your guess, you are right!
But, this gem is at it's infancy. It's trading at a low of $.22. That's right 22 cents!
Could this be the next bio-tech giant?
Below is an article from Yahoo Finance:
SAN DIEGO, CA--(Marketwired - Apr 6, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is forTreatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Patent application #14588374 covers methods, compositions, and treatment protocols for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F2 gene expression or activity of protein. This patent application also covers induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states. While # 14588373 covers utilizing of gene silencing technologies pertaining to suppression of the nuclear receptor NR2F2 for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors and methods of using such compounds to treat cancer.
These new patent applications add to the Company's existing portfolio of intellectual property covering therapeutics that can be used as differentiation therapy, a new form of cancer treatment that works by instructing cancer stem cells to mature in to normal cells that have a limited lifespan. This intellectual property will compliment other intellectual property in the Gene Silencing of Cancer Stem Cells Therapeutics Platform including in-house and acquired IP from the University of Toronto for the cancer stem cell gene NR2F6 (also known as EAR-2) and the Company's CTCFL technology also known as BORIS).
We are working on establishing an area of expertise in Gene Silencing of Cancer Stem Cell target genes, that builds upon a licensing agreement with Benitec Biopharma for use in conjunction with their shRNA gene silencing platform. This allows us to take advantage of synergisms by establishing strengths and programs that we can use to comprehensively target the important genes in the cancer stem cell space. This will lead to economies of scale in therapy development.
The cancer stem cell is the most important and sought after cellular target of cancer therapy. Not every cancer cell within a tumor is able to divide. Cancer stem cells are the cells within the tumor that can divide an infinite number of times and are the cells within the tumor that allow a tumor to maintain its cancerous ability, therefore it is important to target those cells specifically.
"Patent protection is also essential for thoroughly protecting the Company's space in this field. While existing patents cover NR2F6, a closely related member of that protein family, NR2F2 has some redundant and overlapping functions. Protecting this space is important not only to cover our target, but because resistance of the cancer to therapy is one the biggest causes of cancer therapy failure," according to Dr. Thomas Ichim, the Company's Chief Scientific Officer.
"The circuitry of the cell is like a stream. Many times, cancer therapeutics fail because the circuitry of the cell is equipped with redundant pathways that are turned on when the initial pathway is blocked, like the increased flow to tributaries when one branch of a stream is dammed. By silencing the NR2F6 related family member NR2F2 the Company believes that we can create more efficacious therapeutics by prospectively addressing possible mechanisms of resistance before they arise," noted Christine Ichim, PhD, the Company's Director of Molecular Therapeutics.
NR2F2 (COUP-TFII) is well known for its role in cancer by the mechanism of controlling key pathways in embryogenesis and tumor formation including the Notch signalling pathway, TGF-beta and retinoic acid signalling.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK:RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
InvestorTrendz
PS. Please, I encourage you to do your
Someone loading for something
Send me that info on that stock please. MR.LROX@YAHOO.COM
Are u saying more news today
15k in vol.ask=.19 x 48320, bid.1825x7000 on fidelity
Your Funny
Alert I'll sell 11k shares to any1 for $1.5, I'm in need now
Nice pop at .2399